Immunoglobulin A Nephropathy
ZLABZai LabCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Povetacicept (Pove) (APRIL/BAFF Inhibitor) in Immunoglobulin A Nephropathy. The expected timing is based on the latest available company guidance and may change.
08/06/26:- BLA accepted; PDUFA decision target set for November 30, 2026.
Verification
Confirm timing and program details against the company announcement or filing.